From 29 March till 1 April 2023: HIGHLIGHTS ON LUNG CANCER
Your direct line with Copenhagen
On Thursday 30 March 2023 we even had a live broadcast. Prof. Emeritus Johan Vansteenkiste invited an expert panel in Copenhagen to discuss the new ESMO guidelines. Watch the entire broadcast here.
Stay tuned, and get ready for an exciting and informative journey!With the support of Sanofi
Daily highlights
For the last day of the ELCC 2023 congress in Copenhagen, we asked Dr Anouk Goudsmit (NKI Amsterdam & Institut Jules Bordet, Brussels) to summarize the presentations of the mini oral session 2 on Friday, March 31. She first discussed the updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3
On the second day in Copenhagen, we asked Dr Koen Deschepper (Vitaz – Oost Vlaanderen) to summarize the most exciting presentations of the proferred paper session. He first discussed the 3-year update of the CheckMate 816 study of neoadjuvant nivolumab in combination with platinum-doublet chemotherapy for resectable NSCLC. A second
Dr Mariana Brandao (HUB – Institut Jules Bordet) brings from a rainy Copenhagen the first report on the highlights of day 1 at the ELCC congress. She briefly describes three studies. The Apple study investigated the feasibility of longitudinal plasma EGFR T790M monitoring and the best sequencing strategy from gefitinib
In-depth stories
During the 2023 edition of ELCC, Dr Mariana Brandao from the Institut Jules Bordet in Brussels summarized the educational session on a very hot topic in lung cancer treatment in
Dr Charlotte De Bondt from the University Hospital Antwerp comments on the first results of the CARMEN-LC05-study. At ELCC 2023, data on the efficacy and safety of tusamitamab ravtansine in
During the ELCC Congress 2023 in Copenhagen, Prof Em Johan Van Steenkiste (UZ Leuven) had a meeting Prof Martin Reck, president of this year’s ELCC and Head of the Department
During our reports at the European Lung Cancer Congress 2023 in Copenhagen, the MediMix team had the opportunity to do an in-depth interview with Prof Nicolas Girard from the Institut
Poster selection
Exciting preliminary results from the LUMINANCE study were presented at the ELCC 2023 conference. The phase 3b, single-arm study investigated the efficacy of durvalumab +
Dr. Pierre van Mol from the KU Leuven Laboratory for Translational Genetics presented his research at ELCC 2023, which revealed that a low CXCL10:IL-8 ratio
At ELCC 2023, Louise Berteloot from the Innovation Centre RADar at the AZ Delta in Belgium presented her work on the development of an explainable
At ELCC 2023, Marc Terrones from the University of Antwerp presented his research on dissecting the molecular landscape of resistance to ROS1 TKIs using improved
